Exploring Genetic Roots of Neurodevelopmental and Psychiatric Disorders
NIMH’s new project uses stem cells to explore 250 risk genes for neurodevelopmental and psychiatric disorders.
Complete the form below to unlock access to ALL audio articles.
Summary
The NIMH has launched a major project to study 250 risk genes for neurodevelopmental and psychiatric disorders using human stem cells. By creating and analyzing stem cell lines with specific gene mutations, researchers aim to understand the genetic factors behind conditions like schizophrenia and autism and improve treatment options.
Key Takeaways
Neurodevelopmental and psychiatric disorders (NPD) including schizophrenia, bipolar disorder, autism, and depression are detrimental to individuals, their families and society as a whole, and in many cases still lack effective treatments. It’s becoming more and more clear that genetic mutations in certain genes can increase the likelihood of developing NPD, and several hundreds of those “risk genes” have been identified to date, but their role related to NPD remains a mystery. “Very little is known about the basic function of most of these genes, and what we do know often comes from work in cancer cell lines rather than brain cell types,” says David Panchision, Chief of the Developmental and Genomic Neuroscience Research Branch at the National Institute of Mental Health (NIMH), who spearheaded the SSPsyGene program aiming to tackle this challenge. “As such, we still don’t have a clear understanding of how alterations in these genes may work individually or in combination to contribute to neurodevelopmental and psychiatric disorders.”
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREETo get to the bottom of this, the National Institute of Mental Health (NIMH) initiated a consortium called SSPsyGene (sspsygene.ucsc.edu) in 2023, uniting research teams from renowned US universities with the joint goal of characterizing the genetic origins of NPD, focusing on 250 selected high-risk genes. Among the contributors are Jubao Duan, Endeavor Health (formerly NorthShore University Health System) and University of Chicago, USA and Zhiping Pang, Rutgers University, USA with their teams, who developed a method for mutating NPD risk genes in human stem cells at large scale. In the modified cells, a selected NPD risk gene is mutated so that it no longer makes a functional protein. The modified stem cells can subsequently be turned into neurons and other brain cells to model the consequences of risk gene mutations in a simplified, lab-based version of the human brain. In the initial phase of the project, the teams tested 23 NPD risk genes, reported in work published in a recent article in the journal Stem Cell Reports. The resulting stem cell lines will be made available to other researchers worldwide to facilitate research on those risk genes and their contribution to NPD. In future works, Pang, Duan and the other members of the consortium will join forces to generate mutated stem cell lines for a much larger number of risk genes, with the ultimate goal of understanding the genetic causes for NPD and for generating better treatments. “The hope is that this collaborative work will generate a highly impactful resource for the neuroscience and psychiatric research community,” Panchision says.
Reference: Zhang H, McCarroll A, Peyton L, et al. Scaled and efficient derivation of loss-of-function alleles in risk genes for neurodevelopmental and psychiatric disorders in human iPSCs. Stem Cell Rep. doi: 10.1016/j.stemcr.2024.08.003
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.